^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy

Excerpt:
An 84-gene GS associated with clinical response for MAGE-A3 immunotherapeutic was identified in metastatic melanoma and confirmed in resected NSCLC.
DOI:
10.1200/JCO.2012.44.3762
Trial ID: